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 X-1 Brain tumors 
 A brain tumor is an intracranial neoplasm that has various pathologies 
(1).Using diagnostic information, a tumor can be classified as least aggressive 
(benign) to most aggressive (malignant). In most cases, a brain tumor is named 
for the cell type of origin or its location. Identifying the type ofbrain tumor helps 
to determine the most appropriate course of treatment. 
There are three main types of brain tumors: intra-medullary, 
extra-medullary, and metastatic.  Most intra-medullary tumors originate from 
glial cells and are called gliomas.A glioma is generally infiltrative into the brain 
parenchyma; therefore, a complete surgical excision is usually difficult. The 
prognosis of patients with a glioma depends on the malignancy grade of the 
tumor; although, it is generally poor. On the other hand, most extra-medullary 
brain tumors are benign and complete surgical removal results in a good 
prognosis. Metastatic brain tumors are always malignant and although the 
prognosis depends on a patient’s systemic condition, it is generally poor. 
 
 
 X-2 Diagnosis of brain tumors 
The main symptoms of brain tumors are headache, paresis, and epileptic 
seizures. A progressive clinical course suggests a brain tumor. An accurate 
preoperative diagnosis of the tumor pathology and malignancy grade is often 
challenging. Most intra-medullary tumors are malignant; however, they may be 
benign; while, the majority of extra-medullary tumors are benign,but malignant 
tumors also exist. Selecting an appropriate treatment depends on the 
malignancy grade and prognosis of the tumor; thus, a correct preoperative 
diagnosis is important. The final diagnosis depends on the pathological analysis 
of the surgical specimen. 
 
X-3 Radiological diagnosis of brain tumors 
Brain magnetic resonance imaging (MRI) is the modality of choice for 
evaluating patients who have symptoms and signs suggesting a brain tumor and 
for assessing the tumor location and extent. Even if most clinical questions can 
be answered by MRI and computed tomography (CT), these techniques have 
limitations in the characterization of brain lesions, defining the tumor extent, 
therapy monitoring, and in detecting the recurrence or progression of tumors. 
High contrast enhancement in a tumor means high blood flow but not 
necessarily malignancy. Meningioma and pituitary adenomas are typical benign 
extra-medullary tumors with high contrast enhancement. In addition, complete 
visualization of infiltrating malignant glioma cells is difficult, even with high 
resolution MRI. 
The brain neoplasms are treated with various combinations of surgery, 
radiation, and chemotherapy. Changes that follow treatment may include edema 
and radiation necrosis, and it is often challenging to differentiate between tumor 
recurrence and such benign physical changes with CT or MRI(2-5). Nuclear 
medicine imaging allows in vivo investigation of tumor metabolism, given the 
wide availability of radiotracers, and plays a major role in the diagnosis and 
follow-up of patients with brain tumors. 
 
X-4 SPECT for the diagnosis and evaluation of brain tumors 
Single photon emission computed tomography (SPECT) is a valuable 
diagnostic modality for the evaluation of the brain tumor malignancy grade and 
activity.Thallium-201 (Tl) and two Technetium-99m labeled 
radiopharmaceuticals (methoxyisobutylisonitrile (Tc-MIBI) and tetrofosmin 
(TF))have been clinically used with SPECT to evaluate brain tumors. SPECT 
has also been used with the radioactive labeled amino acid 
3-[123I]iodo-a-methyl-L-tyrosine for the diagnosis of brain tumors and 
evaluation of tumor response to radiation therapy. 
 
X-4-1 Tl SPECT 
Tl, a potassium analog, is taken up by viable tumor cells but not by necrotic 
tissue or non-proliferating glial cells(6).It is cyclotron produced with a physical 
half-life of 73 hours. Tl has been used in myocardial scintigraphy and in 
evaluating lung carcinomas and brain tumors. Tl SPECT is useful for identifying 
the presence of a tumor (7), grading of the tumor malignancy(3, 4, 6),and 
distinguishing tumor recurrence from radiation necrosis (2-4)(Figure 1).The 
SPECT procedure involves imaging approximately 20-30 minutes following 
injection of 74-148 MBq of Tl. Occasionally, a 2-hour delayed Tl acquisition may 
be helpful as the abnormal tumor tissue would be expected to washout more 
slowly than normal brain tissue (8, 9).The SPECT imaging should be done using 
a low energy general purpose collimator. The photopeak should be centered at 
80 and 167 keV. The Tl index, the ratio of counts in the lesion region of interest 
(ROI) to counts in the contralateral ROI, is used to differentiate between low and 
high grade gliomas(6) as well as between recurrence and radiation necrosis (11, 
12).The value of these ratios varies according to the identification of the ROI, 
the location and size of the lesion, and whether or not there is central necrosis. 
Some investigators recommend drawing the ROI over the highest pixel counts 
of Tl uptake; while, others recommend drawing it over the inner and outer border 
of the tumor and averaging the pixel counts. Ratios above 1.6-2.4 may indicate 
malignant lesions; while, lower ratios indicate either benign lesions or early 
recurrence (13).In a population of 90 patients with supratentorial brain tumors, 
the overall sensitivity and specificity of Tl in detecting the lesions were 71.7% 
and 80.9% respectively(14).Dynamic Tl SPECT is useful to evaluate tumor 
vascularity, histopathology, and malignancy (15, 16).The utility of Tl SPECT in 
differentiating toxoplasmosis from lymphoma in AIDS patients was 
demonstrated by Kessler et al.(17) with a sensitivity of 100% and specificity of 
93%.  
The utility of Tl SPECT as an early predictor of outcome in patients with 
recurrent gliomas has been shown by Vos et al.They reported that at baseline 
and follow-up, maximal tumor intensity by Tl SPECT was the strongest 
predictive variable and was inversely related to overall survival as well as 
progression-free survival. They also showed a progression of maximal tumor 
intensity after two courses of chemotherapy was a powerful predictor of poor 
outcome. For a Tl-avid lesion that has been treated and shown to be Tl negative 
on follow-up, any Tl uptake is an indicator of tumor recurrence(13).Glioma 
surgery may improve the prognosis, but this is controversial, possibly due to the 
method of evaluating glioma surgical extent. In a study from our group, we 
evaluated the glioma surgical extent using fusion images of preoperative Tl 
SPECT with postoperative MRI to predict the prognosis of the patients regarding 
the removal rate and postsurgical residual tumor.  All patients received 
standard adjuvant radiation and chemotherapy after surgery. We found the 
fusion image of preoperative Tl SPECT and postoperative MRI was more useful 
for evaluating glioma removal extent than just MRI. Patients with partial removal 
had a poor prognosis; thus, the aim should be for maximum surgical removal 
using multimodal images including MRI and Tl SPECT. The total removal of Tl 
SPECT positive lesions improves the prognosis and prevents early 
recurrence(18). 
Inflammation after surgery or radiation is a major cause of false 
positives(3, 4, 19-21). Other inflammatory lesions, like brain abscesses, can be 
also a source of a false positive scan(22) (Figure 2). Using combined Tl 
and 99mTc–hexamethylpropyleneamine oxime (Tc-HMPAO) for brain tumors has 
been recommended to increase the specificity of Tl SPECT (2, 23). Carvalho et 
al. assessed the ability of sequential Tl and Tc-HMPAO SPECT to distinguish 
tumor recurrence from radiation changes after high-dose radiation therapy for 
malignant gliomas. The authors found Tc-HMPAO SPECT is useful for 
identifying the absence of solid tumor recurrence in patients with low to 
moderate Tl uptake (ratio 1.1 to 3.4) and low perfusion to that site (less than 
0.5.)(23).  
 
Some causes of false negative findings may include small tumor size; located 
centrally or adjacent to areas of physiological tracer uptake, such as choroid 
plexus; histological heterogeneity; and cystic or necrotic components (24, 
25).Young et al.(25) reported that when using a Tl-index > 2 in lesions bigger 
than 2 cm, Tl SPECT has a 100% sensitivity and 89% specificity for the 
differentiation between brain lymphoma and toxoplasmosis in patients with 
AIDS; while, the sensitivity and specificity were 50% and 82%, respectively, in 
lesions smaller than 2 cm.  
Both central neurocytomas and gangliogliomas are benign gliomas with a high 
Tl uptake (26)(27). High cell density and high metabolic rate are thought to 
explain the high Tl uptake in these low proliferative tumors. In our series, one 
patient with a central neurocytoma showed high Tl uptake and no Tc-MIBI 
uptake (Figure 3). In this case, Tc-MIBI SPECT was more accurate than Tl 
SPECT to evaluate tumor malignancy. Pilocytic astrocytoma is one of the most 
benign gliomas and the Tl SPECT findings show variable uptake (28). Lower Tl 
uptake is also observed in early follow-up studies after surgical excisions and/or 
aggressive chemotherapy. This is due to granulation tissue and new vascularity 
associated with treatment(13) 
 
 
 
X-4-2 Tc-MIBI SPECT 
Tc-MIBI is a lipophilic cationic complex with a physical half-life of 6 hours, 
initially designed for myocardial perfusion SPECT.  Tc-MIBI SPECT is also 
useful to diagnose brain tumor recurrence (29, 30);evaluate the biological 
characteristics of brain tumors(31), tumor volume, and survival (32, 33); and in 
the differential diagnosis of radiation necrosis(5). As with Tl imaging, the Tc-MIBI 
index can be used to differentiate between low and high grade gliomas (34) as 
well as recurrence and radiation necrosis (29), and to estimate the prognosis 
(32, 33). Tc-MIBI is concentrated in the mitochondria as the result of active 
diffusion due to increased metabolic needs (29). Its uptake is affected by tumor 
malignancy, viability, density, oxygenation, vascular supply, and blood brain 
barrier (BBB) disruption (35). These factors are not linearly correlated because 
glioblastoma, the most malignant form of glioma, is pathologically 
heterogeneous and includes internal necrosis. 
In Tc-MIBI SPECT, tumor imaging occurs approximately 20-30 minutes 
following injection of about 740 MBq Tc-MIBI.Delayed images (2-4 h p.i.) have 
been also recommended. The SPECT imaging should be done using a low 
energy general purpose collimator and the photopeak should be centered at 140 
keV. In the brain, Tc-MIBI is taken up by normal choroid plexus, scalp, the 
pituitary gland, and nasopharyngeal tissues (36). 
With respect to the histological type, a higher Tc-MIBI retention index has been 
noted in glioblastoma multiforme compared with metastatic tumors. In addition, 
while Tc-MIBI SPECT shows high uptake and retention in malignant gliomas, 
washout from metastatic brain tumors is faster than from glioblastomas(37). 
Tc-MIBI has also been successfully used in high-grade gliomas to distinguish 
recurrent tumor from radionecrosis (30) and when the results of both CT and 
MRI are difficult to interpret, because of inflammation resulting from surgery or 
radiation, and offer only an imperfect indication of tumor viability(38).  A false 
negative finding by MIBI SPECT may occur due to an intact BBB. (30). In a 
study on patients in the pre-surgical phase for interparenchymal brain tumors, 
Tc-MIBI SPECT identified tumors in the fronto-temporal regions more easily 
than in the temporal regions or in the posterior fossa (36). P-glycoprotein is a 
drug efflux pump in the cell membrane and it acts to remove Tc-MIBI from tumor 
cells (40, 41). Other studies have suggested that p-glycoprotein expression in 
malignant gliomas may cause false negative results in Tc-MIBI SPECT 
(42-44).However, the effect of p-glycoprotein expression on clinical Tc-MIBI 
SPECT images has been investigated, and the effect was negligible in the 
diagnosis of brain tumor malignancy (45). Henze also reported that 
p-glycoprotein efflux does not contribute to falsely negative MIBI SPECT, since 
MIBI washout did not occur between the early and late SPECT scans (46). 
Some of the false positive results were due to recent radiation induced 
local disruption of the BBB (30). Tc-MIBI shows early accumulation into the 
normal choroid plexus and good wash out from it. .Choroid plexus papillomas 
show slower tracer wash out than the normal choroid plexus;hence, the delayed 
MIBI index is higher than the early MIBI index(47). 
 
X-4-2-1 Comparison of Tl and MIBI brain SPECT in patients with gliomas 
The diagnostic values of brain Tl and Tc-MIBI SPECT have been evaluated by 
our group using sensitivities and specificities with arbitrary cut off values. The 
diagnostic ability of Tl SPECT and Tc-MIBI SPECT were directly compared for 
patients with an initial glioma using ROC analysis. The study population 
included 59 patients with gliomas. The benign group included patients with low 
grade astrocytomas and central neurocytomas; while,the malignant group 
included patients with anaplastic astrocytomas and glioblastomas. All patients 
underwent  Tl and Tc-MIBI SPECT and tumor/not-tumor (T/N) ratios were 
calculated. The area z-score(Az) values were calculated from the areas under 
the ROC curves (Figure 4). The delayed Tc-MIBI had the highest Az while the 
early MIBI had the lowest Az. Both Tl and MIBI SPECT are considered useful 
imaging modalities for the evaluation of glioma malignancies. Delayed MIBI 
SPECT demonstrated better diagnostic value in patients with gliomas based on 
ROC analysis; although,the difference was not statistically significant(48). 
Some studies have reported that Tc-MIBI SPECT has higher sensitivity and 
specificity than Tl SPECT for adult and childhood brain tumors and for the 
differential diagnosis of recurrence and radiation necrosis (5, 33, 38); however, 
other studies disagree(37). This discrepancy may be caused by small and 
heterogeneous patient populations and arbitrarily selected cut off values. In Tl 
SPECT, there is some normal brain uptake, which makes the T/N ratio low. 
Tc-MIBI has a high photon energy level and higher T/N ratio in comparison with 
Tl SPECT and yields clear SPECT images with high sensitivity for malignant 
brain tumors(5, 29, 38).  
 
 
 X-4-3 Tc-Tetrofosmin SPECT 
TF is a lipophilic cationic tracer with a physical half-life of 6 hours that 
was initially used for myocardial perfusion SPECT. The utility of TF in evaluation 
of brain tumors has been demonstrated(49-52). Soricelli et al. (49) showed 
significant agreement among Tl and TF SPECT for the diagnosis of brain 
tumors; however, the image quality, contrast, and the definition of tumor margins 
obtained by TF were superior to those with Tl. TF is also useful for non-invasive 
grading.  There was a striking difference between the TF index in low grade 
and high grade gliomas, which was not the case for Tl, Tc-MIBI, and 18F-FDG 
PET(53). TF can also distinguish tumor recurrence from radiation 
necrosis(50-52).We compared the radiological image findings from TF and Tl 
SPECT for 11 patients with brain tumors.The tracer uptakes of TF and Tl were 
almost matched. In the patients with meningioma, both TF and Tl early images 
showed high uptake and these tracers were washed out in delayed images 
(Figure 5). Both TF and Tl delayed SPECT images showed high uptake in 
tumors from patients with glioblastomas(Figure 6).  
There is physiological TF uptake in the normal choroid plexus, which 
contributes to the spatial correlation between tumors and ventricles. TF SPECT 
is better and more useful than Tl SPECT to diagnose tumor location, extent, 
malignancy, viability, and effects from therapies(54). 
 
X-4-4:3-[123I]iodo-a-methyl-L-tyrosine SPECT 
3-[123I]iodo-a-methyl-L-tyrosine (123I-IMT) is an amino acid SPECT 
tracer for brain imaging.Tumors are imaged with SPECT approximately 10 
minutes after the injection of 370-740 MBq 123I-IMT. To prevent the uptake of 
free iodine, the thyroid should be blocked with 400-600 mg sodium perchlorate 
30 minutes before tracer application. The SPECT imaging should be done using 
a low energy high resolution collimator using a 20% energy window centered on 
the 159-keV photopeak.123I-IMT SPECT was directly compared with 
[methyl-11C]-L-methionine (MET) PET in 14 patients with cerebral gliomas(55). 
Visual comparison of the scans yielded no differences in tumor size and shape 
with both methods. The tumor to brain ratios of 123I-IMT SPECT and MET PET 
showed a significant correlation especially in the early, transport dominated 
phase at 15 min after injection. 
Kuwert et al.(56) showed that 123I-IMT SPECT may aid in differentiating 
high-grade gliomas from histologically benign brain tumors and non-neoplastic 
brain lesions; however, this modality was inappropriate for distinguishing 
non-neoplastic from benign lesions. In this study, the sensitivity and specificity of 
123I-IMT SPECT were 71% and 83%, respectively, for differentiating high grade 
from low grade gliomas, 82% and 100%, respectively, for distinguishing 
high-grade gliomas from non-neoplastic lesions, and 50% and 100%, 
respectively, for discriminating low-grade gliomas from non-neoplastic 
lesions(56). 
The utility of 123I-IMT SPECT for determining tumor grade and prognosis 
of the disease is controversial(56-60). A strong correlation between tracer 
uptake and tumor proliferative activity was reported by Kuwert etal.(59). In 
contrast,Weber et al.(61) reported that 123I-IMT uptake appeared not to 
correlate with the biological aggressiveness of tumor cells in patients with 
unresectable high-grade gliomas. Nevertheless, the clear association between 
focal 123I-IMT uptake after tumor resection and poor survival suggests that 
123I-IMT is a specific marker for residual tumor tissue(61).  
It is very important to precisely determine the tumor extent for planning 
surgery or radiation. 123I-IMT is taken up in brain areas with an intact 
blood-brain barrier and IMT SPECT appears to be able to image the infiltrating 
tissue of cerebral gliomas like MET(62).In a study using IMT SPECT in addition 
to MRI for planning radiation therapy, a larger tumor volume was detected by 
123I-IMT SPECT than by conventional MRI. The authors highlighted that 
IMT-SPECT investigations improved tumor detection and delineation in the 
treatment planning process (63). 
Several studies yielded good sensitivity and specificity of IMT SPECT for 
the detection of viable tumor tissue in previously treated patients (57, 58, 64). 
Bader et al. showed that 123I-IMT SPECT was equivalent to a stereotactic 
biopsy in its ability to identify high-grade tumors at recurrence (57).The fusion of 
123I-IMT SPECT images with MRI improves the interpretation of the findings 
and may increase the specificity of the investigation(65). In addition, 123I- 
IMT-SPECT was a promising complementary imaging tool for the detection of 
recurrences of non-astrocytic intracranial tumors and for distinguishing them 
from treatment induced changes(66). Several studies indicate the utility of 
123I-IMT in the follow-up of patients with brain tumors (57, 64, 67). Patients with 
recurrence had significantly higher ratios of 123I-IMT  uptake in the tumor area 
to that in the background region than patients without recurrence. The majority 
of brain metastases exhibit high 123I-IMT uptake, which does not allow 
differentiation from gliomas. A combination of 123I-IMT  and Tl SPECT, 
however, may be able to distinguish high-grade gliomas from other malignant 
brain lesions, like metastases, with high accuracy (68). 
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